帕金森病眼动追踪技术的最新进展（2022 - 2024年）：一种用于诊断和监测症状的有前景的工具。
Recent advances (2022-2024) in eye-tracking for Parkinson's disease: a promising tool for diagnosing and monitoring symptoms.
作者信息
Culicetto Laura, Cardile Davide, Marafioti Giulia, Lo Buono Viviana, Ferraioli Francesca, Massimino Simona, Di Lorenzo Giuseppe, Sorbera Chiara, Brigandì Amelia, Vicario Carmelo Mario, Quartarone Angelo, Marino Silvia
机构信息
IRCCS Centro Neurolesi "Bonino-Pulejo", Messina, Italy.
Dipartimento di Scienze Cognitive, Psicologiche, Pedagogiche e Degli Studi Culturali, Università Degli Studi di Messina, Messina, Italy.
出版信息
Front Aging Neurosci. 2025 May 21;17:1534073. doi: 10.3389/fnagi.2025.1534073. eCollection 2025.
INTRODUCTION
Parkinson's disease (PD) is one of the most prevalent neurodegenerative disorders, characterized by both motor and non-motor symptoms, including impaired oculomotor functions. Eye-tracking technology, a precise and non-invasive method for measuring eye movements, has emerged as a promising tool for diagnosing and monitoring PD progression. This systematic review evaluates the effectiveness of eye-tracking in assessing motor and cognitive alterations associated with PD.
METHODS
A systematic review of the literature was conducted using PubMed, Web of Science, Embase, Scopus and Cochrane Library databases to identify studies applying eye-tracking to assess oculomotor functions in PD patients. Only articles published from 2022 to 2024 were considered.
RESULTS
A total of 10809 studies were identified. 18 met the inclusion criteria and were included. Findings indicate that eye-tracking may offer valuable insights into both oculomotor and cognitive dysfunctions. Specific metrics such as saccade velocity, fixation duration, and pupil size have been correlated with disease severity. Recent technological advancements, including the integration of machine learning (ML) and virtual reality (VR), have further enhanced the diagnostic accuracy and scalability of eye-tracking methods.
CONCLUSION
In the past 3 years, eye-tracking has rapidly advanced, particularly through its integration with ML and VR. These innovations have enhanced precision, accessibility, and clinical relevance. Emerging evidence also supports its potential to detect eye movement biomarkers associated with disease stage, motor subtypes, and cognitive decline. This review synthesizes the latest findings, underscoring the role of eye-tracking as a scalable and personalized tool for PD assessment. However, further efforts are needed to address challenges such as protocol standardization and device variability.
SYSTEMATIC REVIEW REGISTRATION
https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42024602802, identifier CRD42024602802.
引言
帕金森病（PD）是最常见的神经退行性疾病之一，其特征在于运动和非运动症状，包括动眼功能受损。眼动追踪技术是一种精确且非侵入性的测量眼动方法，已成为诊断和监测帕金森病进展的有前景的工具。本系统评价评估了眼动追踪在评估与帕金森病相关的运动和认知改变方面的有效性。
方法
使用PubMed、Web of Science、Embase、Scopus和Cochrane图书馆数据库对文献进行系统评价，以识别应用眼动追踪评估帕金森病患者动眼功能的研究。仅考虑2022年至2024年发表的文章。
结果
共识别出10809项研究。18项符合纳入标准并被纳入。研究结果表明，眼动追踪可能为动眼和认知功能障碍提供有价值的见解。诸如扫视速度、注视持续时间和瞳孔大小等特定指标已与疾病严重程度相关。最近的技术进步，包括机器学习（ML）和虚拟现实（VR）的整合，进一步提高了眼动追踪方法的诊断准确性和可扩展性。
结论
在过去3年中，眼动追踪技术迅速发展，特别是通过与ML和VR的整合。这些创新提高了精度、可及性和临床相关性。新出现的证据也支持其检测与疾病阶段、运动亚型和认知衰退相关的眼动生物标志物的潜力。本综述综合了最新研究结果，强调了眼动追踪作为一种可扩展且个性化的帕金森病评估工具的作用。然而，需要进一步努力应对诸如协议标准化和设备变异性等挑战。
系统评价注册
https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42024602802，标识符CRD42024602802。
Zotero 插件